Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms

Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench

(2017) Kenichi Suda et al.   Journal of Thoracic Oncology

Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC

(2017) Kai Chen et al.   Journal of Thoracic Oncology

Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis

(2017) Chee Khoon Lee et al.   Journal of Thoracic Oncology

Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells

(2017) Yuichi Sesumi et al.   LUNG CANCER

Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo

(2017) Kenichiro Kudo et al.   Molecular Oncology

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

(2017) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer

(2017) Ken Uchibori et al.   Nature Communications

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

(2017) Rafael Rosell et al.   Lancet Respiratory Medicine

Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer

(2016) Hiroshi Mizuuchi et al.   CANCER SCIENCE

Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors

(2016) S. Ortiz-Cuaran et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

(2016) Ying Cheng et al.   JOURNAL OF CLINICAL ONCOLOGY

Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies

(2016) Meghan Campo et al.   Journal of Thoracic Oncology

Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment

(2016) Jun Soo Ham et al.   Journal of Thoracic Oncology

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature

(2016) Caicun Zhou et al.   Journal of Thoracic Oncology

New and emerging targeted treatments in advanced non-small-cell lung cancer

(2016) Fred R Hirsch et al.   LANCET

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment

(2016) Puey Ling Chia et al.   LUNG CANCER

Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer

(2016) Kenichi Suda et al.   LUNG CANCER

High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression

(2016) Sai-Hong Ignatius Ou et al.   LUNG CANCER

Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors

(2016) Yong Jia et al.   NATURE

A framework for understanding and targeting residual disease in oncogene-driven solid cancers

(2016) Trever G Bivona et al.   NATURE MEDICINE

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

(2016) Aaron N Hata et al.   NATURE MEDICINE

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation

(2016) Chaolun An et al.   PATHOLOGY & ONCOLOGY RESEARCH

Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing

(2016) Ying Jin et al.   Oncotarget

Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells

(2016) Y. Ohue et al.   Cancer Immunology Research

First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer

(2016) Keunchil Park et al.   JAMA Oncology

ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

(2016) Takeshi Yoshida et al.   PLoS One

Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902

(2015) S. Sugawara et al.   ANNALS OF ONCOLOGY

EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients

(2015) D. Planchard et al.   ANNALS OF ONCOLOGY

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

(2015) M. Schuler et al.   ANNALS OF ONCOLOGY

Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity

(2015) Kenichi Suda et al.   ARCHIVES OF TOXICOLOGY

EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer

(2015) Kyoko Otsuka et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition

(2015) M. Soucheray et al.   CANCER RESEARCH

Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib

(2015) Shinsuke Hashida et al.   CANCER SCIENCE

Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR

(2015) M. Watanabe et al.   CLINICAL CANCER RESEARCH

Impact of bevacizumab in combination with erlotinib onEGFR-mutated non-small cell lung cancer xenograft models with T790M mutation orMETamplification

(2015) Koh Furugaki et al.   INTERNATIONAL JOURNAL OF CANCER

Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient

(2015) Matthias Scheffler et al.   Journal of Thoracic Oncology

Mechanisms of Acquired Resistance to AZD9291

(2015) Tae Min Kim et al.   Journal of Thoracic Oncology

Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy

(2015) Shintaro Kanda et al.   LUNG CANCER

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR -mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI

(2015) Samuel J. Klempner et al.   LUNG CANCER

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

(2015) Kenneth S Thress et al.   NATURE MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer

(2015) B. Halmos et al.   ONCOLOGIST

Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer

(2015) E. M. Tricker et al.   Cancer Discovery

IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer

(2015) Yi-Nan Liu et al.   Oncotarget

Acquired Resistance ofEGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor

(2015) Helena A. Yu et al.   JAMA Oncology

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

(2014) Yi-Long Wu et al.   LANCET ONCOLOGY

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

(2014) Takashi Seto et al.   LANCET ONCOLOGY

Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations

(2014) Y. Y. Janjigian et al.   Cancer Discovery

Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell-like Properties in Cancer Cells

(2013) K. Shien et al.   CANCER RESEARCH

Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model

(2013) Hiromi Hayakawa et al.   CANCER SCIENCE

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Acquired Resistance to Targeted Therapies Against Oncogene-Driven Non–Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications

(2013) David R. Gandara et al.   Clinical Lung Cancer

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

(2013) Helena A. Yu et al.   Journal of Thoracic Oncology

Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma

(2013) Satoshi Watanabe et al.   LUNG CANCER

Loss of an EGFR-amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells

(2013) Koh Furugaki et al.   LUNG CANCER

Surgery for NSCLC in the era of personalized medicine

(2013) Tetsuya Mitsudomi et al.   Nature Reviews Clinical Oncology

Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

(2013) S. B. Goldberg et al.   ONCOLOGIST

A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop

(2013) K E Ware et al.   Oncogenesis

Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation—diversity, ductility, and destiny

(2012) Kenichi Suda et al.   CANCER AND METASTASIS REVIEWS

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib

(2012) Ming-Hung Huang et al.   Molecular Oncology

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

(2012) K. Ohashi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors

(2012) Dalia Ercan et al.   Cancer Discovery

Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib

(2011) Kenichi Suda et al.   Journal of Thoracic Oncology

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma

(2011) Hidetaka Uramoto et al.   LUNG CANCER

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation

(2010) Kenichi Suda et al.   CANCER AND METASTASIS REVIEWS

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

(2010) Alexa B. Turke et al.   CANCER CELL

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer

(2010) K. Suda et al.   CLINICAL CANCER RESEARCH

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance

(2009) G. N. Naumov et al.   CLINICAL CANCER RESEARCH

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase

(2008) T. Okabe et al.   MOLECULAR CANCER THERAPEUTICS